Kymera Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
KYMR$136.64-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
STOCKHOLDERS’ EQUITY
(In thousands, except for share amounts)
| Common Stock · AdditionalPaid in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Value | Capital | Deficit | Income/(Loss) | Equity | |
| Balance at December 31, 2024 | 64,890,193 | $7 | $1,591,707 | $(754,610) | $(1,485) | 835,619 |
| Exercise of stock options | 75,652 | — | 535 | — | — | 535 |
| Vesting restricted stock | 146,869 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 14,233 | — | — | 14,233 |
| Unrealized gain on marketable securities | — | — | — | — | 1,427 | 1,427 |
| Net loss | — | — | — | (65,581) | — | (65,581) |
| Balance at March 31, 2025 | 65,112,714 | $7 | $1,606,475 | $(820,191) | $(58) | $786,233 |
| Balance at December 31, 2025 | 81,323,532 | $8 | $2,643,817 | $(1,065,961) | $1,800 | $1,579,664 |
| Exercise of stock options | 669,517 | — | 19,194 | — | — | 19,194 |
| Vesting restricted stock | 189,052 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 16,007 | — | — | 16,007 |
| Unrealized loss on marketable securities | — | — | — | — | (5,994) | (5,994) |
| Net loss | — | — | — | (69,234) | — | (69,234) |
| Balance at March 31, 2026 | 82,182,101 | $8 | $2,679,018 | $(1,135,195) | $(4,194) | $1,539,637 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.